A Phase 4 Study of Zytiga in Poor-risk mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients Who Was Failed the First-line CAB (Combined Androgen Blockade) Therapy

Trial Profile

A Phase 4 Study of Zytiga in Poor-risk mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients Who Was Failed the First-line CAB (Combined Androgen Blockade) Therapy

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Abiraterone acetate (Primary) ; Prednisolone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Janssen Pharmaceutical KK
  • Most Recent Events

    • 14 Jul 2017 Planned End Date changed from 31 Mar 2017 to 31 Dec 2018.
    • 14 Jul 2017 Planned primary completion date changed from 31 Mar 2017 to 31 Dec 2018.
    • 14 Jul 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top